Stoke Therapeutics, Inc.
STOK
$31.27
-$0.04-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -496.12% | -437.70% | 92.26% | 138.47% | 150.68% |
| Total Depreciation and Amortization | -12.32% | -17.17% | -18.70% | -16.88% | -16.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.34% | 25.77% | 22.29% | 12.55% | 10.53% |
| Change in Net Operating Assets | 53.35% | -29.11% | 158.09% | -135.38% | -285.56% |
| Cash from Operations | -388.95% | -311.13% | 152.49% | 162.68% | 177.04% |
| Capital Expenditure | -497.12% | -153.94% | -230.05% | -23.08% | 32.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 106.38% | -43.86% | -73.52% | -33.63% | -239.15% |
| Cash from Investing | 104.72% | -44.22% | -73.82% | -33.58% | -235.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,605.30% | 37.93% | -25.71% | -95.93% | -91.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,605.30% | 37.93% | -25.71% | -95.93% | -91.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.48% | -220.50% | 30.67% | -66.34% | -6,581.50% |